Takezako Yoriko, Okusaka Takuji, Ueno Hideki, Ikeda Masahumi, Morizane Chigusa, Najima Mina
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1443-6.
There are a variety of tumor markers used for diagnosis of pancreatic and biliary tract cancer including carbohydrate antigens such as CA19-9, DUPAN-2, CA50 and Span-1, the carcinoembryonic antigen and pancreatic enzymes such as elastase 1. The tumor marker kinetics in serum help to predict survival in patients receiving surgical and/or non-surgical treatment. Since each of those tumor markers remains at a low sensitivity and specificity in the early stage, none are useful for detecting early cancer. In spite of the development of various diagnostic techniques, pancreas and biliary tract cancer is usually diagnosed at an incurable stage, and the 5-year survival rate is extremely low. Therefore, improvements in survival may well result from screening for early-stage pancreatic and biliary cancer. The development of tumor markers with higher sensitivity and specificity should have the highest priority.
有多种肿瘤标志物可用于诊断胰腺癌和胆管癌,包括糖类抗原,如CA19-9、DUPAN-2、CA50和Span-1、癌胚抗原以及胰腺酶,如弹性蛋白酶1。血清中的肿瘤标志物动力学有助于预测接受手术和/或非手术治疗患者的生存期。由于这些肿瘤标志物在早期的敏感性和特异性都较低,因此没有一种对早期癌症检测有用。尽管各种诊断技术不断发展,但胰腺癌和胆管癌通常在无法治愈的阶段才被诊断出来,5年生存率极低。因此,早期筛查胰腺癌和胆管癌有望提高生存率。开发具有更高敏感性和特异性的肿瘤标志物应成为首要任务。